Details of Drug

Drug General Information (ID: D0177)
Drug Name	Bevacizumab
Drug Type	Monoclonal antibody
Drug Synonymous	Bevacizumab (ophthalmic slow-release tissue tablet) Click to Show/Hide
Disease Class	2A00-2F9Z: Solid tumour/cancer; 2B91: Colorectal cancer; 2C25: Lung cancer; 2D50-2E2Z: Metastatic tumour; 2C73: Ovarian cancer
Therapeutic Class	Vegf/Vegfr Inhibitors
External Link
External Link	TTD ID	D04KBL

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM043 Additive immunosuppressive effects BM044 Additive myelosuppressive effects BM047 Additive thrombogenic effects BM107 Attenuated pharmacological effects (Unspecific) BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Bevacizumab
Pharmacodynamic additive effects
	Additive immunosuppressive effects					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1375		Radium Ra 223 dichloride	NA	NA	Moderate		Inter Info	[28]
D1487		Sodium phosphate, monobasic (p32)	NA	NA	Moderate		Inter Info	[30]
D1509		Strontium chloride Sr-89	Cl2Sr	5388879	Moderate		Inter Info	[1], [4], [31]
D1610		Topotecan	C23H23N3O5	60700	Moderate		Inter Info	[32]
D1855		Palifermin	NA	NA	Moderate		Inter Info	[36]
	Additive myelosuppressive effects					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0433		Deferiprone	C7H9NO2	2972	Major		Inter Info	[1], [2], [3]
D1443		Samarium (153Sm) lexidronam	Sm	23951	Major		Inter Info	[6]
	Additive thrombogenic effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1220		Panitumumab	NA	NA	Major		Inter Info	[4], [3], [5]
D1522		Sunitinib	C22H27FN4O2	5329102	Major		Inter Info	[7], [8], [9]
D0034		Alendronic acid	C4H13NO7P2	2088	Moderate		Inter Info	[1], [4], [26]
D0623		Etidronic acid	C2H8O7P2	3305	Moderate		Inter Info	[1], [4], [26]
D0783		Ibandronate	C9H23NO7P2	60852	Moderate		Inter Info	[1], [4], [26]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[27]
D1217		Pamidronic acid	C3H11NO7P2	4674	Moderate		Inter Info	[1], [4], [26]
D1412		Risedronic acid	C7H11NO7P2	5245	Moderate		Inter Info	[1], [4], [26]
D1426		Romosozumab	NA	NA	Moderate		Inter Info	[29]
D1584		Tiludronic acid	C7H9ClO6P2S	60937	Moderate		Inter Info	[1], [4], [26]
D1727		Zoledronic acid	C5H10N2O7P2	68740	Moderate		Inter Info	[1], [4], [26]
Pharmacodynamic antagonistic effects
	Attenuated pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0659		Filgrastim	NA	NA	Moderate		Inter Info	[33], [34], [35]
D1235		Pegfilgrastim	C27H46N4O19	70683024	Moderate		Inter Info	[37], [38]
D1446		Sargramostim	NA	NA	Moderate		Inter Info	[33], [34], [35]

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
3	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5	Product Information. Vectibix (panitumumab). Amgen USA, Thousand Oaks, CA.
6	Product Information. Quadramet (samarium sm 153 lexidronam) Berlex Laboratories, Richmond, CA.
7	Product Information. Avastin (bevacizumab). Genentech, South San Francisco, CA.
8	Bevacizumab + sunitinib associated with MAHA.?React. Wkly.?1211, 2 (2008).
9	Genentech Inc.Microangiopathic hemolytic anemia (MAHA) in patients treated with Avastin (Rm) (bevacizumab) and sunitinib malate. Internet Document: [2 pages], Jul 2009.
10	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
11	Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6. [PMID: 12459408]
12	Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3. [PMID: 12229885]
13	Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711. [PMID: 11992318]
14	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
15	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
16	Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9. [PMID: 12860952]
17	Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2. [PMID: 11419443]
18	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
19	Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23. [PMID: 12409330]
20	Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8. [PMID: 12043695]
21	Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9. [PMID: 12506164]
22	Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5. [PMID: 11520815]
23	Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21. [PMID: 15327525]
24	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
25	Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36. [PMID: 12365009]
26	Product Information. Sutent (sunitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
28	Product Information. Xofigo (radium Ra 223 dichloride). Bayer Pharmaceutical Inc, West Haven, CT.
29	Product Information. Evenity (romosozumab). Amgen USA, Thousand Oaks, CA.
30	AnazaoHealth Corporation "P32 Sodium Phosphate."
31	Multum Information Services, Inc. Expert Review Panel.
32	Product Information. Hycamtin (topotecan). SmithKline Beecham, Philadelphia, PA.
33	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
34	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
35	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.
36	Product Information. Kepivance (palifermin). Shire US Inc, Florence, KY.
37	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
38	Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence